All In Biotech

Drug Trial Radar · NCT07937020

Topical Lactoferrin and Luliconazole, Alone or in Combination, for Tinea Corporis

Efficacy and Safety of Combined Topical Lactoferrin and Luliconazole Therapy Versus Topical Luliconazole Monotherapy in Egyptian Patients With Tinea Corporis: A Double-Blind Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Kafrelsheikh UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial will compare three cream treatments for tinea corporis, also called ringworm of the body. It will include Egyptian adults aged 18 to 65 years whose skin infection is confirmed by examining a skin scraping under a microscope. The main questions are: * Does using lactoferrin cream with luliconazole cream clear the infection better than either cream alone? * What side effects occur with each treatment? * Does the infection return after treatment? Participants will be assigned by chance to one of three groups: * Lactoferrin 2% cream and luliconazole 1% cream. * Luliconazole 1% cream and a matching cream without lactoferrin. * Lactoferrin 2% cream and a matching cream without luliconazole. The matching creams contain no active study ingredient and help keep treatment assignments hidden. Participants and the researchers assessing their skin will not know which treatment each participant receives. Participants will apply their assigned creams twice daily for four weeks. They will attend study visits for skin examinations, symptom assessments, and monitoring for side effects. Skin scrapings will be examined to check whether the infection has cleared. Researchers will also assess changes in the size of the affected areas, itching, treatment satisfaction, and whether the infection returns.

Conditions

  • Tinea Corporis

Interventions

  • Lactoferrin 2% CreamDrug

    Topical cream containing lactoferrin 2% w/w, prepared in the Pharmaceutics Laboratory, Faculty of Pharmacy, Kafrelsheikh University. Applied to the affected areas twice daily for four weeks, before luliconazole cream or its matching placebo, according to treatment allocation.

  • Luliconazole 1% CreamDrug

    Topical cream containing luliconazole 1% w/w. Applied to the affected areas twice daily for four weeks, after lactoferrin cream or its matching placebo, according to treatment allocation.

  • Lactoferrin-Matching Placebo CreamDrug

    Vehicle cream without lactoferrin, matching the active lactoferrin cream in appearance, consistency, packaging, and labeling. Applied to the affected areas twice daily for four weeks before luliconazole 1% cream.

  • Luliconazole-Matching Placebo CreamDrug

    Vehicle cream without luliconazole, matching the active luliconazole cream in appearance, consistency, packaging, and labeling. Applied to the affected areas twice daily for four weeks after lactoferrin 2% cream.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Clinical CureTime frame: Week 6 after treatment initiation (2 weeks after treatment completion)
  2. Percentage of Participants Achieving Mycological CureTime frame: Week 6 after treatment initiation (2 weeks after treatment completion)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kafrelsheikh University Hospital

    Kafr ash Shaykh, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.